Biotech
-
How a scrapped Pfizer drug became a winner for SpringWorks
SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.
By Alexandra Pecci • April 21, 2025 -
A big moment is coming for psychedelics
Compass Pathways expects to publish the first phase 3 results from a large-scale, psilocybin drug trial by the end of this quarter.
By Meagan Parrish • April 18, 2025 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineTech for Clinical Trials
Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.
By PharmaVoice staff -
Amid an onshoring push, Raleigh is poised to be pharma’s next manufacturing hub
Lower operating costs and a supply of high-skilled workers are helping the North Carolina region pull in billions of pharma manufacturing investments.
By Alexandra Pecci • April 16, 2025 -
‘Chaos’ in the biotech market has dampened hopes of a rebound. What does that mean for dealmaking and IPOs?
The biotech market is taking a beating amid Trump’s turbulent economic policies.
By Amy Baxter • April 15, 2025 -
US risks losing biotech edge to China, report warns
“There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S. to invest at least $15 billion into the sector over the next five years.
By Ned Pagliarulo • April 9, 2025 -
Profile
Her son’s DMD diagnosis shook her world. As a biotech CEO, it was also an epiphany for better rare disease R&D.
Five years ago, Michelle Werner received her son’s Duchenne muscular dystrophy diagnosis with fear and desperation. Now, as CEO of Alltrna, she’s finding better ways to develop treatments.
By Michael Gibney • April 8, 2025 -
A birth control pill for men makes moves in the clinic
So far, the science and safety seem solid. But is the world emotionally ready to shift the responsibility of contraception to men?
By Kelly Bilodeau • April 7, 2025 -
The year’s biggest biotech haul shows investors are still chasing the AI dream
Isomorphic Labs recently raked in $600 million to help develop its drug discovery platform.
By Meagan Parrish • April 4, 2025 -
Opinion
Industry leaders react to HHS being ‘reduced to a shell’
What healthcare watchdogs have said about the far-reaching job cuts this week.
By Meagan Parrish and Amy Baxter • April 3, 2025 -
Profile
Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions’
Dr. Mikael Dolsten, Pfizer’s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.
By Michael Gibney • April 1, 2025 -
With government health info in limbo, drugmakers lose credible sources
The lack of clear communication from the government could spark wide-ranging issues in pharma — from sowing confusion about clinical trial design to further eroding public trust.
By Alexandra Pecci • April 1, 2025 -
A recent gene therapy death shines a light on AAV safety
This technology brings both benefits and drawbacks for the field, which is also testing alternatives.
By Kelly Bilodeau • March 31, 2025 -
How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology
After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.
By Michael Gibney • March 27, 2025 -
Biogen plots new global headquarters in Kendall Square
The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.
By Jacob Bell • March 25, 2025 -
Biotechs emerging from stealth take aim at pharma’s prime targets
The companies are striving to bring fresh innovations to cancer care, pain management and the weight loss space.
By Kelly Bilodeau • March 24, 2025 -
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.
By Michael Gibney • March 20, 2025 -
The key factors shaping China’s biopharma boom
Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.
By Alexandra Pecci • March 19, 2025 -
Q&A
How non-traditional investors fuel up-and-coming biotechs when VC funding dries up
Smaller biotechs are finding creative ways to fund R&D at a time when the traditional financing channels have become more constrictive.
By Michael Gibney • March 18, 2025 -
Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do
Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.
By Kelly Bilodeau • March 17, 2025 -
Q&A
Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s
The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.
By Amy Baxter • March 17, 2025 -
IRA reforms, including a small molecule fix, could be on the table. Will Trump and the GOP make the leap?
Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.
By Amy Baxter • March 12, 2025 -
The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep
Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.
By Amy Baxter • March 11, 2025 -
What’s driving pharma’s layoffs in 2025
Familiar foes in the industry have claimed a slew of jobs in recent months.
By Meagan Parrish • March 10, 2025 -
The time is ripe for pharma M&A. Why are drugmakers holding out?
The M&A resurgence has been predicted for years, but the industry is still holding out, partly because the ideal range for biotech valuations has been harder to find.
By Michael Gibney • March 6, 2025 -
With patent losses on the horizon, Amgen refocuses its business strategy
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”
By Alexandra Pecci • March 5, 2025